First Citizens Bank & Trust Co. Increases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

First Citizens Bank & Trust Co. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,704 shares of the biopharmaceutical company’s stock after buying an additional 681 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Halozyme Therapeutics were worth $225,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics during the third quarter worth approximately $57,000. FSC Wealth Advisors LLC purchased a new position in Halozyme Therapeutics during the third quarter worth approximately $65,000. Park Place Capital Corp raised its stake in Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 1,209 shares during the period. Finally, CWM LLC boosted its holdings in shares of Halozyme Therapeutics by 77.5% in the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 668 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on HALO shares. HC Wainwright upped their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $56.00 on Wednesday. The firm has a 50-day moving average of $50.08 and a two-hundred day moving average of $54.27. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The stock has a market cap of $7.12 billion, a P/E ratio of 18.54, a PEG ratio of 0.42 and a beta of 1.24. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.